Jun 07, 2017
Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform London (UK) / Mechelen (Belgium), 7 June 2017 – MRC Technology (‘MRCT’), a medical research charity, and Biocartis Group NV (‘Biocartis’ or the ‘Company’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced a partnership to develop selected molecular diagnostic tests for use on Biocartis’ fully automated Idylla™ platform. MRCT aims ...
Read More
Jun 06, 2017
BBI Solutions, in partnership with Merck and Kinematic Automation, is hosting a lateral flow seminar designed to provide a practical insight into lateral flow test development. Taking place from the 6th to the 8th of June at the Fota Island Resort in Cork, Ireland, this event is aimed at industry professionals, and will cover various aspects of assay development and commercialisation, as well as offering a hands-on experience in test design.
Read More
Jun 02, 2017
BBI Solutions (BBI) has invested into its facilities and resource in order to increase the capacity of cell culture transferrin production by up to 40%.
Read More
May 25, 2017
Oxford, UK – 25 May 2017. Oxford Gene Technology (OGT), The Molecular Genetics Company, has made several advances in hybridisation-based target enrichment protocols that now enable researchers to prepare samples for sequencing in just one day. Researchers can now access the high-quality results of hybridisation-based targeted sequencing with a speed comparable to that of amplicon-based approaches.
Read More
May 25, 2017
The IMMY CrAg® LFA (Cryptococcal Antigen Lateral Flow Assay) is the first and only immunochromatographic dipstick assay for the qualitative and semi-quantitative detection of the cryptococcal capsular antigen in serum, plasma and cerebrospinal fluid (CSF).
Read More
May 16, 2017
Belgium, 16 May 2017 – Multiplicom, an Agilent Technologies Company, announced today the extended CE-IVD certification of its BRCA MASTR Plus Dx. This next-generation molecular diagnostic solution uniquely detects both germline* (inherited) and somatic (acquired) mutations in BRCA1 and BRCA2 genes. In combination with the MASTR Reporter, both an analysis software and a quality control tool, it is the one solution for all BRCA mutation testing needs.
Read More
May 08, 2017
SpeciSafe® secondary packaging containers provide a safe, convenient and economical solution for UN3373 compliant mailing of biological and clinical specimens. The extensive range includes solutions for screw cap microtubes, vacuum blood collection tubes, cryovials, Universal and Bijou containers, plus swabs/transport tubes.
Read More
May 08, 2017
Cardiff, UK – 2nd May 2017 – EKF Diagnostics, the global in vitro diagnostics company, announces that it is expanding the distribution of its Procalcitonin LiquiColor® Test into Eastern Europe, Middle East and APAC regions. Procalcitonin (PCT) is a marker for bacterial infection and sepsis, a condition that has grown in awareness in recent years. PCT is now widely recognized as an important adjunct marker in sepsis diagnosis which aids in the differentiation between viral and bacterial infecti...
Read More
May 02, 2017
BBI Solutions is pleased to announce that it has triumphed at the DxMA’s 2017 Dx Creative Awards, winning the New IVD Product Launch (less than $100m) category for the market release of its Morffi™ signal enhancement technology. The awards ceremony (held in New Orleans, USA, on the 30th of April) was an opportunity to celebrate the latest innovations in the diagnostics field ahead of the DxMA Global Marketing Summit on the 1st of May, where BBI’s Dr Neil Polwart was also presenting the compan...
Read More
Apr 24, 2017
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed an agreement with Thermo Fisher Scientific, the world leader in serving science. The announcement was made at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna to submit its ResistancePlus MG Test for the detection of Mycoplasma genitalium to the US Food & Drug Administration (FDA).
Read More
Page 8 of 9 [8]